We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · April 17, 2021

No Benefit of Bimagrumab in Sporadic Inclusion Body Myositis

Neurology

 

Additional Info

Neurology
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT
Neurology 2021 Mar 23;96(12)e1595-e1607, AA Amato, MG Hanna, PM Machado, UA Badrising, H Chinoy, O Benveniste, AK Karanam, M Wu, LB Tankó, AA Schubert-Tennigkeit, DA Papanicolaou, TE Lloyd, M Needham, C Liang, KA Reardon, M de Visser, DP Ascherman, RJ Barohn, MM Dimachkie, JAL Miller, JT Kissel, B Oskarsson, NC Joyce, P Van den Bergh, J Baets, JL De Bleecker, C Karam, WS David, M Mirabella, SP Nations, HH Jung, E Pegoraro, L Maggi, C Rodolico, M Filosto, AI Shaibani, K Sivakumar, NA Goyal, M Mori-Yoshimura, S Yamashita, N Suzuki, M Aoki, M Katsuno, H Morihata, K Murata, H Nodera, I Nishino, CD Romano, VSL Williams, J Vissing, L Zhang Auberson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading